HUP9903584A3 - Salts of quinoline derivatives as nk3 antagonists - Google Patents
Salts of quinoline derivatives as nk3 antagonistsInfo
- Publication number
- HUP9903584A3 HUP9903584A3 HU9903584A HUP9903584A HUP9903584A3 HU P9903584 A3 HUP9903584 A3 HU P9903584A3 HU 9903584 A HU9903584 A HU 9903584A HU P9903584 A HUP9903584 A HU P9903584A HU P9903584 A3 HUP9903584 A3 HU P9903584A3
- Authority
- HU
- Hungary
- Prior art keywords
- antagonists
- salts
- quinoline derivatives
- quinoline
- derivatives
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
- C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9524137.8A GB9524137D0 (en) | 1995-11-24 | 1995-11-24 | Novel compounds |
| PCT/EP1996/005210 WO1997019928A1 (en) | 1995-11-24 | 1996-11-22 | Salts of quinoline derivatives as nk3 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP9903584A2 HUP9903584A2 (hu) | 2000-02-28 |
| HUP9903584A3 true HUP9903584A3 (en) | 2001-10-29 |
Family
ID=10784449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9903584A HUP9903584A3 (en) | 1995-11-24 | 1996-11-22 | Salts of quinoline derivatives as nk3 antagonists |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US6355654B1 (hu) |
| EP (1) | EP0876348B1 (hu) |
| JP (1) | JP4377454B2 (hu) |
| KR (1) | KR19990071599A (hu) |
| CN (1) | CN1207728A (hu) |
| AR (1) | AR004970A1 (hu) |
| AT (1) | ATE233243T1 (hu) |
| AU (1) | AU722451B2 (hu) |
| BR (1) | BR9611729A (hu) |
| CA (1) | CA2238312A1 (hu) |
| CZ (1) | CZ158198A3 (hu) |
| DE (1) | DE69626416T2 (hu) |
| ES (1) | ES2192621T3 (hu) |
| GB (1) | GB9524137D0 (hu) |
| HU (1) | HUP9903584A3 (hu) |
| IL (1) | IL124352A0 (hu) |
| MX (1) | MX9804106A (hu) |
| NO (1) | NO310866B1 (hu) |
| NZ (1) | NZ323389A (hu) |
| PL (1) | PL326927A1 (hu) |
| TR (1) | TR199800925T2 (hu) |
| WO (1) | WO1997019928A1 (hu) |
| ZA (1) | ZA969812B (hu) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9825554D0 (en) | 1998-11-20 | 1999-01-13 | Smithkline Beecham Spa | Novel Compounds |
| US7037922B1 (en) * | 2000-03-10 | 2006-05-02 | Neurogen Corporation | Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands |
| EP1165542B1 (en) | 1999-03-29 | 2003-08-20 | Neurogen Corporation | 4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands |
| AU4802500A (en) | 1999-04-26 | 2000-11-10 | Neurogen Corporation | 2-aminoquinolinecarboxamides: neurokinin receptor ligands |
| AU2006253054A1 (en) * | 2005-06-03 | 2006-12-07 | Astrazeneca Ab | Quinoline derivatives as NK3 anatgonists |
| GB0515580D0 (en) | 2005-07-29 | 2005-09-07 | Merck Sharp & Dohme | Therapeutic compounds |
| WO2007016609A2 (en) * | 2005-08-02 | 2007-02-08 | Smithkline Beecham Corporation | Method for the synthesis of quinoliνe derivatives |
| US20080280949A1 (en) * | 2005-08-11 | 2008-11-13 | Astrazeneca Ab | Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators |
| WO2007035156A1 (en) * | 2005-09-21 | 2007-03-29 | Astrazeneca Ab | N-oxo-heterocycle and n-oxo-alkyl quinoline-4-carboxamides as nk-3 receptor ligands |
| AR057130A1 (es) * | 2005-09-21 | 2007-11-14 | Astrazeneca Ab | Quinolinas de alquilsulfoxido y una composicion farmaceutica |
| TW200804288A (en) | 2005-12-12 | 2008-01-16 | Astrazeneca Ab | Alkylsulphonamide quinolines |
| CN101410392A (zh) * | 2006-01-27 | 2009-04-15 | 阿斯利康(瑞典)有限公司 | 酰胺取代的喹啉类化合物 |
| FR2979173B1 (fr) * | 2011-08-19 | 2013-08-16 | St Microelectronics Grenoble 2 | Commutateur analogique basse tension |
| IN2014CN03234A (hu) | 2011-11-03 | 2015-07-03 | Merck Sharp & Dohme | |
| AU2014255512A1 (en) | 2013-04-19 | 2015-11-12 | Astrazeneca Ab | A NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS) |
| WO2017072629A1 (en) | 2015-10-29 | 2017-05-04 | Cadila Healthcare Limited | Pharmaceutical combination of nk3 receptor antagonist and biguanides |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL186075B1 (pl) * | 1994-05-27 | 2003-10-31 | Smithkline Beechem Spa | N-(-etylobenzylo)-3-hydroksy-2-fenylochinolino-4-karboksyamid oraz kompozycja farmaceutyczna zawierająca ten związek |
| IT1270615B (it) * | 1994-07-14 | 1997-05-07 | Smithkline Beecham Farma | Uso di derivati di chinolina |
-
1995
- 1995-11-24 GB GBGB9524137.8A patent/GB9524137D0/en active Pending
-
1996
- 1996-11-21 AR ARP960105281A patent/AR004970A1/es unknown
- 1996-11-22 TR TR1998/00925T patent/TR199800925T2/xx unknown
- 1996-11-22 KR KR1019980703875A patent/KR19990071599A/ko not_active Application Discontinuation
- 1996-11-22 JP JP52016097A patent/JP4377454B2/ja not_active Expired - Fee Related
- 1996-11-22 CA CA002238312A patent/CA2238312A1/en not_active Abandoned
- 1996-11-22 US US09/077,152 patent/US6355654B1/en not_active Expired - Fee Related
- 1996-11-22 AU AU10319/97A patent/AU722451B2/en not_active Ceased
- 1996-11-22 PL PL96326927A patent/PL326927A1/xx unknown
- 1996-11-22 DE DE69626416T patent/DE69626416T2/de not_active Expired - Lifetime
- 1996-11-22 ES ES96941026T patent/ES2192621T3/es not_active Expired - Lifetime
- 1996-11-22 CZ CZ981581A patent/CZ158198A3/cs unknown
- 1996-11-22 CN CN96199611A patent/CN1207728A/zh active Pending
- 1996-11-22 IL IL12435296A patent/IL124352A0/xx unknown
- 1996-11-22 NZ NZ323389A patent/NZ323389A/en unknown
- 1996-11-22 WO PCT/EP1996/005210 patent/WO1997019928A1/en not_active Application Discontinuation
- 1996-11-22 ZA ZA9609812A patent/ZA969812B/xx unknown
- 1996-11-22 HU HU9903584A patent/HUP9903584A3/hu unknown
- 1996-11-22 BR BR9611729A patent/BR9611729A/pt unknown
- 1996-11-22 EP EP96941026A patent/EP0876348B1/en not_active Expired - Lifetime
- 1996-11-22 AT AT96941026T patent/ATE233243T1/de not_active IP Right Cessation
-
1998
- 1998-05-22 MX MX9804106A patent/MX9804106A/es unknown
- 1998-05-22 NO NO19982332A patent/NO310866B1/no not_active IP Right Cessation
-
2001
- 2001-11-06 US US09/994,076 patent/US6432977B1/en not_active Expired - Fee Related
-
2002
- 2002-06-12 US US10/167,881 patent/US20020156097A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR9611729A (pt) | 1999-04-06 |
| JP4377454B2 (ja) | 2009-12-02 |
| TR199800925T2 (xx) | 2001-05-21 |
| CA2238312A1 (en) | 1997-06-05 |
| EP0876348B1 (en) | 2003-02-26 |
| AU722451B2 (en) | 2000-08-03 |
| US6432977B1 (en) | 2002-08-13 |
| US6355654B1 (en) | 2002-03-12 |
| WO1997019928A1 (en) | 1997-06-05 |
| CN1207728A (zh) | 1999-02-10 |
| EP0876348A1 (en) | 1998-11-11 |
| AR004970A1 (es) | 1999-04-07 |
| GB9524137D0 (en) | 1996-01-24 |
| HUP9903584A2 (hu) | 2000-02-28 |
| NZ323389A (en) | 2000-02-28 |
| US20020156097A1 (en) | 2002-10-24 |
| NO982332D0 (no) | 1998-05-22 |
| NO310866B1 (no) | 2001-09-10 |
| ZA969812B (en) | 1998-05-22 |
| US20020077335A1 (en) | 2002-06-20 |
| MX9804106A (es) | 1998-09-30 |
| IL124352A0 (en) | 1998-12-06 |
| DE69626416T2 (de) | 2003-12-24 |
| JP2000500770A (ja) | 2000-01-25 |
| DE69626416D1 (de) | 2003-04-03 |
| ATE233243T1 (de) | 2003-03-15 |
| CZ158198A3 (cs) | 1998-10-14 |
| PL326927A1 (en) | 1998-11-09 |
| ES2192621T3 (es) | 2003-10-16 |
| KR19990071599A (ko) | 1999-09-27 |
| AU1031997A (en) | 1997-06-19 |
| NO982332L (no) | 1998-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL317381A1 (en) | Derivatives of quinoline as antagonists of tachykynin receptors nk3 | |
| CY2505B1 (en) | Quinoline derivatives as nk3 antagonists | |
| PL326967A1 (en) | Quinoline derivatives | |
| HUP9802940A2 (hu) | Kinolin-2(1H)-on-származékok mint szerotoninantagonisták | |
| IL124352A0 (en) | Salts of quinoline derivatives as nk3 antagonists | |
| GR3036346T3 (en) | BENZO[g]QUINOLINE DERIVATIVES | |
| IL128141A0 (en) | Tetrahydroquinoline derivatives as eaa antagonists | |
| PL326636A1 (en) | Derivatives of quinoline as inhibitors of type iv phosphodiesterase | |
| PL333079A1 (en) | Piparazinic derivatives as antagonists of neurokinin | |
| GB9404378D0 (en) | Quinoline derivatives | |
| ZA954269B (en) | Quinoline derivatives | |
| GB9402275D0 (en) | Quinoline derivatives | |
| GB9413150D0 (en) | Quinoline derivatives | |
| PL330723A1 (en) | Derivatives of benzo[g]quinoline | |
| HU9900343D0 (en) | Use of quinoline derivatives having tachycinin nk3 receptor antagonist | |
| PL318106A1 (en) | Quinoline derivatives as antagonists of leucotrienes | |
| SI0940391T1 (en) | Quinoline derivatives as tachykinin NK3 receptor antagonists | |
| GB9402306D0 (en) | Quinoline derivatives | |
| GB9413937D0 (en) | Quinoline derivatives | |
| IL126806A0 (en) | Quinoline derivatives | |
| SI0839136T1 (en) | BENZO(g)QUINOLINE DERIVATIVES |